WuXi XDC Cayman Inc (2268) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of WuXi XDC Cayman Inc stock HK$43.26, price HK$69.35, that is 37.6% below the price, quality 49 out of 100. Rating: strongly overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
WuXi XDC Cayman Inc
2268 · HKFar too expensive (fair value 38% below the price) and weak company, but rising price: meets 1 of 3 rules.
Main risks:
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.
How to read this chart
36‑month range HK$12.98 – HK$85.10 · fair‑value band HK$30.78 – HK$59.34 · the HK$69.35 price screens above the HK$43.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.
Every Wednesday you see whether WuXi XDC Cayman is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
Show moreShow less
It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services.
Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China.
WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Stock analysis
WuXi XDC Cayman Inc (2268) currently trades at HK$69.35, while our model-based Fair Value estimate is HK$43.26, 38% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$59.14 per share, and 0 of the 24 models we run sit above the HK$69.35 price.
Bear case: the Asset-Based group reads lowest at HK$5.67, and 24 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$30.78 (bear) to HK$59.34 (bull), the price of HK$69.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
WuXi XDC Cayman Inc reported revenue of 5.9B CNY in FY2025 versus 311M CNY in FY2021, a compound +109.1%/yr. Reported net income was 1.5B CNY in FY2025, compounding +127.9%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap HK$95.0B (≈ $12.1B) Large · P/E ratio 59.5 · P/S ratio 14.8 · Net margin 24.9% · Return on equity 16.3% · Return on assets (EBIT) 7.8% (5-year average) · Operating margin 29.6% · Revenue (TTM) 6.9B CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 51% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −38%, 2268 screens richer than that median.
Fair Value models
All 24 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
2268 screens overvalued: fair value 38% below the price. Compare with Thermo Fisher Scientific Inc →
Earlier news
- WuXi XDC Cayman (SEHK:2268) Stock May Be 32% Undervalued Despite ADC Awards
- WuXi XDC Named the Winner of "Best CDMO" for the Fourth Consecutive Year and the Winner of "Best CRO" for the Second Consecutive Year
- Antibody-Drug Conjugates (ADC) CDMO Market Report: Evaluating End-to-End Bioconjugation, HPAPI Synthesis, and Strategies of Lonza, WuXi XDC,
- WuXi XDC Cayman (SEHK:2268) Secures GMP Release At New Singapore Site
Compare WuXi XDC Cayman Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 150 stocks
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Materials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- PEG ratio by industry
- Revenue growth by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| WuXi AppTec Co 603259 | ¥146.30 | ¥164.66 | +13% | vs 2268 |
| IQVIA Holdings IQV | $265.12 | $291.63 | +10% | vs 2268 |
| Illumina, Inc ILMN | $207.01 | $227.71 | +10% | vs 2268 |
| Thermo Fisher Scientific Inc TMO | $700.22 | $686.04 | −2% | vs 2268 |
| Danaher Corporation DHR | $233.02 | $209.18 | −10% | vs 2268 |
| IDEXX Laboratories, Inc IDXX | $704.23 | $496.48 | −30% | vs 2268 |
| Lonza Group LONN | CHF 666.00 | CHF 259.80 | −61% | vs 2268 |
| Mettler-Toledo International Inc MTD | $1,739 | $655.06 | −62% | vs 2268 |
| Agilent Technologies, Inc A | $173.96 | $64.53 | −63% | vs 2268 |
| Waters Corporation WAT | $460.25 | $91.26 | −80% | vs 2268 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is WuXi XDC Cayman Inc (2268) overvalued or undervalued?
What is the fair value of 2268?
What is the quality score of 2268?
What is the price target for WuXi XDC Cayman Inc (2268)?
What is the WuXi XDC Cayman Inc stock forecast for 2026?
What is the revenue of WuXi XDC Cayman Inc (2268)?
What growth is priced into WuXi XDC Cayman Inc (2268)?
What discount rate (WACC) does the fair value of 2268 use?
What is a reverse DCF?
How much growth has WuXi XDC Cayman Inc (2268) delivered so far?
How fast is the sector of WuXi XDC Cayman Inc (2268) growing?
What is the free cash flow yield of WuXi XDC Cayman Inc (2268)?
What is the intrinsic value of WuXi XDC Cayman Inc (2268)?
Is WuXi XDC Cayman Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2268?
How much is WuXi XDC Cayman Inc worth?
What do the bullish and bearish scenarios say about 2268?
What is the P/E ratio of 2268?
How solid is the balance sheet of WuXi XDC Cayman Inc (2268)?
How far is 2268 from its 52-week high?
Which stocks are comparable to WuXi XDC Cayman Inc?
Is WuXi XDC Cayman Inc stock attractive at the current price?
How is the fair value of 2268 calculated?
Is it still worth investing in stocks now?
What is the share price of WuXi XDC Cayman Inc (2268)?
What should I pay attention to with WuXi XDC Cayman Inc right now?
Key figures of WuXi XDC Cayman Inc
How large is the market capitalisation of WuXi XDC Cayman Inc (2268)?
What is the P/S ratio of WuXi XDC Cayman Inc (2268)?
What is the net margin of WuXi XDC Cayman Inc (2268)?
What is the return on equity of WuXi XDC Cayman Inc (2268)?
What is the EBIT return on assets of WuXi XDC Cayman Inc (2268)?
What is the operating margin of WuXi XDC Cayman Inc (2268)?
How fast is revenue growing at WuXi XDC Cayman Inc (2268)?
How fast are earnings growing at WuXi XDC Cayman Inc (2268)?
How much net cash does WuXi XDC Cayman Inc (2268) hold?
Watch WuXi XDC Cayman Inc in the live analysis
One click puts WuXi XDC Cayman Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.